Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology) in press
www.jzus.zju.edu.cn; www.springer.com/journal/11585
E-mail: jzus_b@zju.edu.cn

Research Article

https://doi.org/10.1631/jzus.B2300899

Efficient genome editing in Medaka (*Oryzias latipes*) using a codon optimized SaCas9 system

Yuewen JIANG[1], Qihua PAN[2], Zhi WANG[1], Ke LU[1], Bilin XIA[1], Tiansheng CHEN[1,2]✉

[1] *College of Fisheries, Key Laboratory of Freshwater Animal Breeding, Ministry of Agriculture and Rural Affairs, Huazhong Agricultural University, Wuhan 430070, China*
[2]*State Key Laboratory of Mariculture Breeding, Engineering Research Center of the Modern Technology for Eel Industry, Ministry of Education, Key Laboratory of Healthy Mariculture for the East China Sea, Ministry of Agriculture and Rural Affairs, Fisheries College of Jimei University, Xiamen 361021, China*

Abstract: The CRISPR-Cas9 system, belonging to the type II CRISPR/Cas system, is an effective gene editing tool widely used in different organisms, but the size of SpCas9 is quite large (4.3 kb), which is not convenient for vector delivery. In this study, we used a codon-optimized SaCas9 system to edit the *tyr*, *oca2*, and *pax6.1* genes in the fish model medaka (*Oryzias latipes*), in which the size of SaCas9 (3.3 kb) is much smaller and the necessary prototype spacer-adjacent motif (PAM) sequence is 5'-NNGRRT-3'. We also used a tRNA-sgRNA system to express the functional sgRNA by transcription either *in vivo* or *in vitro*, and the combination of SaCas9 and tRNA-sgRNA was used to edit the *tyr* gene in the medaka genome. The SaCas9/sgRNA and SaCas9/tRNA-sgRNA systems were shown to edit the medaka genome effectively, while the PAM sequence is an essential part for the efficiency of editing. Besides, tRNA can improve the flexibility of the system by enabling the sgRNA to be controlled by a common promoter such as cytomegalovirus. Moreover, the all-in-one cassette CMV-SaCas9-tRNA-sgRNA-tRNA is functional in medaka gene editing. Taken together, the codon-optimized SaCas9 system provides an alternative and smaller tool to edit the medaka genome and potentially other fish genomes.

Key words: SaCas9; *Medaka;* tRNA; gene editing; *tyr*; *oca2*; *pax6.1*

Unedited

1 Introduction

The clustered regularly interspaced short palindromic repeat/CRISPR-associated (CRISPR/Cas) system is an adaptive immune system in prokaryotes (Makarova et al., 2011a; Wiedenheft et al., 2012). It was later developed as an effective tool for gene editing in multiple species due to its advantages of low cost, easy operation and wide adaptability. The CRISPR-Cas system can be classified into three major types (type I, II, and III): type I and III systems use multi-Cas proteins for target recognition and cleavage while the type II system needs only a single Cas protein (Cas9) to achieve the effect and has become the major genome editing tool (Makarova et al., 2011a; Makarova et al., 2011b; Makarova et al., 2015). Following the application of the CRISPR/Cas9 system to gene editing (Jinek et al., 2012), Emmanuelle Charpentier and Jennifer A. Doudna were awarded the 2020 Nobel Prize in Chemistry, highlighting international recognition of its value. Notably,

✉ Tiansheng CHEN, tiansheng.chen@jmu.edu.cn
Tiansheng CHEN, https://orcid.org/0000-0003-4763-2307
Yuewen Jiang, https://orcid.org/0009-0003-2156-696X

Received Dec. 11, 2023; Revision accepted Mar. 26, 2024;
Crosschecked xxx. xx, 20xx; Published online xxx. xx, 20xx

© Zhejiang University Press 2024

the Cas9 (SpCas9) derived from *Streptococcus pyogenes* has been widely applied for editing the genomes of various organisms (Dickinson et al., 2013; Gratz et al., 2013; Hwang et al., 2013). However, the genome size of SpCas9 is 4.3 kb, which is not easy to pack into the adeno-associated virus vector for therapy or editing, and the protospacer adjacent motif (PAM) is 5'-NGG-3' (Kleinstiver et al., 2015; Mojica et al., 2009).

Alternative Cas9 systems have been developed such as SaCas9 derived from *Staphylococcus aureus*, which is smaller (3.3 kb) and has a different PAM sequence (5'NNGRRT'), and is therefore more suitable for packing and delivery in vivo (Brooks and Gaj, 2018; Friedland et al., 2015; Ran et al., 2015; Wu et al., 2018). Compared to SpCas9, SaCas9 using a 22 nt spacer showed high editing efficiency and lower off-target activities in genome-editing (Xie et al., 2018; Yang et al., 2022). Furthermore, the highest editing efficiency was observed using the spacer with the PAM 5'NNGGGT', while the lowest was observed using the spacer with the PAM 5'NNGGAT' (Yang et al., 2022). A shorter PAM sequence of SaCas9 NNGG was also identified on the application of SaCas9 ortholog (Hu et al., 2020). In addition, the SaCas9 system was able to directly edit the genome, including knockout or gene replacement, in different animal models (Balboa et al., 2017; Feng et al., 2016; Katayama et al., 2020; Wang et al., 2020; Wang et al., 2018; Zhang et al., 2016). However, successful use of the SaCas9 system in the fish model medaka has not yet been reported.

A successful gene editing system needs a functional Cas protein and single guide RNA (sgRNA), and expression of the sgRNA is still a limiting step in different species due to promoter conservation. The discovery of tRNA in both bacterial polycistronic transcriptional units and eukaryotes has shown that tRNA processing systems can produce different small RNAs (Nakaar et al., 1994), while the conserved sequence makes tRNA a universal platform for accurate sgRNA processing (Xie et al., 2015). Compared with the U6 promoter, tRNA is smaller and more suitable for adeno-associated viruses (AAV) vector-based genome editing (Mefferd et al., 2015), and is a potential transcription enhancer of Pol III to improve the editing efficiency of the CRISPR-Cas9 system (Xie et al., 2015). Moreover, the editing ability of a tRNA-sgRNA system has been demonstrated in multiple species, including plants (Ma et al., 2019; Qi et al., 2016), mammals (Dong et al., 2017; Swiech et al., 2015), microorganisms (Numamoto et al., 2017; Zhang et al., 2019), *Drosophila* (Port and Bullock, 2016), zebrafish (Shiraki and Kawakami, 2018), and medaka (Pan et al., 2022). Therefore, the combination of the smaller SaCas9 and tRNA-sgRNA is also desirable approach for gene editing in different species such as the medaka fish model.

The medaka is an excellent fish model, not only for functional genomics, developmental biology, and immunology, but also to test gene function for molecular breeding in aquaculture. We have established an SpCas9 gene editing system in medaka (Fang et al., 2018; Pan et al., 2022). Here, we examined the editing efficiency of a codon-optimized SaCas9 system to mutate three genes including *tyr*, *oca2*, *pax6.1* in medaka, and observed the change in phenotypes and genetic modification by sequencing.

Unedited

2 Materials and methods

2.1 Medaka husbandry and breeding

Medaka fish of the Hd-rR strain were maintained at 28 °C in a water circulation system with a photoperiod of 14 h light :10 h dark (Chen et al., 2017; Pan et al., 2022). Embryos were cultured in embryonic rearing medium until the larvae hatched. All procedures complied with the protocols approved by the Animal Care and Use Committee of Jimei University, Xiamen, China.

2.2 Plasmid construction

Based on the SaCas9 protein sequence (Ran et al., 2015), we optimized the DNA sequence in medaka and defined it as mSaCas9. The coding sequence of mSaCas9, an HA-tag sequence, was inserted into pcDNA3.1 to form plasmid pC322mSaCas9 and synthesized by GenScript Biotech Corp (Supplementary information 1, S1). The mSaCas9 mRNA was synthesized using the mMESSAGE mMACHINE T7 transcription Kit (Thermo).

According to the SaCas9 sgRNA scaffold sequence (Feng et al., 2016; Ran et al., 2015), the target fragment

sgRNA scaffold was annealed using a pair of specific primers cRNA F/cRNA R (Table 1, Figs 1a and 1b). The target fragment sgRNA was amplified by PCR using primers in-gRNA F/Reverse (Table 1, Fig. 1b), and then inserted into the pCS2-tRNA plasmid which was digested by *Bbs* I and *Xho* I (Pan et al., 2022) (Supplementary information 3 and Supplementary information 8, S3 and S8). The PCR programs were set as 94 °C for 3 min, followed by 35 cycles of 94 °C for 25 s, 62 °C for 30 s, and 72 °C for 15 s, then 72 °C for 3 min. The recombinant plasmid pCS2+tRNA-mSatyr-sgRNA was sequenced (Fig. 1c) (Supplementary information 4, S4). Based on the tRNA sequence (Pan et al., 2022), the target fragment in-tRNA was amplified by PCR using primers in-tRNA F/in-tRNA R (Table 1, Fig. 1d), and then inserted into the pCS2+tRNA-mSatyr-sgRNA plasmid digested by *Xho* I (Supplementary information 9, S9). The PCR programs were set as 94 °C for 3 min, followed by 35 cycles of 94 °C for 25 s, 62 °C for 30 s, and 72 °C for 15 s, then 72 °C for 3 min. The recombinant plasmid pCS2+tRNA-mSatyr-sgRNA+tRNA was also sequenced for confirmation (Fig. 1d) (Supplementary information 5, S5).

Based on the plasmid pC322mSaCas9, a tRNA-sgRNA-tRNA sequence was inserted between the SaCas9 and SV40 PolyA to form plasmid pC322mSaCas9+tRNA-tyr sgRNA+tRNA and synthesized by GenScript Biotech Corp (Supplementary information 6, S6). The cassette of mSaCas9+tRNA-tyr sgRNA+tRNA-SV40 PolyA was controlled by CMV and T7 promoters, in which the mRNA of Cas9 and sgRNA can be transcribed from CMV or the T7 promoter.

2.3 mRNA and sgRNA synthesis

The medaka *tyr* sequence (Gene ID: 100049427), *pax6.1* sequence (Gene ID: 100049356), and *oca2* sequence (Gene ID: 100049406) were retrieved from the NCBI website (https://www.ncbi.nlm.nih.gov/) (Chen et al.; Fang et al.; Pan et al., 2023a; Pan et al., 2023b). The spacers were designed using CCTop (https://crispr.cos.uni-heidelberg.de/) and the CRISPOR website (http://crispor.tefor.net/). The PAM sequences of R4414, R4445, R4468, F4553, R14069, R14135, F9011, F9254 were 5'-NNGRRT-3', and those of NR4443 and NR4475 were 5'-NNNNNN-3' (Table 1).

The plasmid pC322mSaCas9 was digested by *Bbs* I as templates for mSaCas9 mRNA, and the mRNA was transcribed using the mMESSAGE mMACHINE T7 transcription Kit (Thermo) (Supplementary information 7, S7). The target fragment T7-sgRNA was amplified by PCR using primers T7-gRNA-cRNA/Reverse (Table 1, Fig. 1b), and sgRNAs were transcribed using the TranscriptAid T7 High Yield Transcription Kit (Thermo Fisher Scientific) (Supplementary information 2, S2). The plasmids pCS2+tRNA-mSatyr-sgRNA and pCS2+tRNA-mSatyr-sgRNA+tRNA were digested by *Not* I as templates for SP6-sgRNAs, and sgRNAs were transcribed using TranscripAid SP6 High Yield Transcription Kits (Thermo Scientific) (Supplementary information 10, S10).

The plasmid pC322mSaCas9+tRNA-tyr sgRNA+tRNA was digested by *EcoR* I as a template for T7-SaCas9-sgRNA, and mRNA-sgRNA was transcribed using the mMESSAGE mMACHINE T7 transcription Kit (Thermo) (Supplementary information 11, S11).

2.4 Medaka embryo microinjection, T7EI assays and sequencing

A mixture containing sgRNA or plasmid, Cas9 mRNA, and 0.05% phenol red was injected into one-cell-stage embryos (Pan et al., 2022). The specific concentrations are shown in Table 2.

The injected embryos were cultured in embryonic rearing medium and imaged with a Leica M205 FA stereomicroscope (Leica, Germany). Heterozygous mutant embryos with a significant phenotype were collected for genotyping. Each pool of embryos was lysed with cell lysis buffer (10 mmol/l Tris-HCl pH 8.0, 75 mmol/l NaCl, 5 mmol/l EDTA, and 0.5% SDS) and proteinase K (100 μg/ml) at 65 °C for 3 h. Proteins and other impurities were removed by adding NH4Ac (7.5 mol/l), and then the DNA was precipitated with isopropanol and resuspended in TE (10 mmol/l Tris-HCl, 1 mmol/l EDTA, pH 8.0) (Pan et al., 2022). The target fragments were amplified by PCR using primers tyr seqF/tyr seqR, oca2 DF/oca2 DR or pax6.1 seqF/ pax6.1 seqR (Table 1). The PCR programs for tyr seqF/tyr seqR were set as 95 °C for 3 min, followed by 35 cycles of 95 °C for 30 s,

Unedited

60 °C for 30 s, and 72 °C for 30 s, then 72 °C for 5 min. The PCR programs for oca2 DF/oca2 DR and pax6.1 seqF/ pax6.1 seqR were set as 95 °C for 3 min, followed by 35 cycles of 95 °C for 30 s, 60 °C for 30 s, and 72 °C for 50 s, then 72 °C for 5 min. The PCR products with a mismatch site were digested by T7 Endonuclease I (EN303-01; Vazyme, China) to detect mutation, and then cloned into pMD18-T (D103A; TaKaRa, Japan) for single-colony sequencing, and the sequence alignment was performed by SnapGene (https://www.snapgene.com/).

2.4 Detection of the genetic inheritance of the mutant

The mutant embryos of F0 were raised to adult fish and were selfed, or hybridized with the *tyr* homozygous mutant (*tyr*$^{-/-}$), which was obtained using the SpCas9 system to knock out the *tyr* gene (Fang et al., 2018). Then, the existence of hypopigmentation in hybrid embryos was observed in both strains, SaCas9 *tyr*$^{-/-}$ and SaCas9 / SpCas9 *tyr*$^{-/-}$. The homozygous mutants of strains were confirmed by sequencing.

3 Results

3.1 Preparation of SaCas9 mRNA, sgRNA and vectors

The plasmid pC322mSaC9 was 8266 bp long (Supplementary data), and the length of mSaCas9 mRNA obtained by in vitro transcription was 3361 nt after being linearized by *Bbs* I. The SaCas9 is driven by the CMV promoter for eukaryotic expression in cells or embryos, and the SaCas9 mRNA can be transcribed by the T7 promoter *in vitro* (Fig. 1a). The sgRNA scaffold template was annealed by oligo pairs, and the DNA of the sgRNA was obtained by PCR using forward and reverse primers. The forward primer contained the T7-spacer and a part sequence of the sgRNA scaffold (Fig. 1b).

The sgRNA expression vector was constructed by infusing the sgRNA fragment with the pCS2-CMV-tRNA vector (Fig. 1c), in which the RNA can be transcribed by the SP6 promoter in the pCS2-CMV-tRNA-sgRNA vector. Moreover, additional tRNA was added to the vector to form the pCS2-CMV-tRNA-sgRNA-tRNA, and the sgRNA was protected by dual tRNAs, front and back (Fig. 1d). All the vectors were confirmed by sequencing.

Unedited

3.2 Knocking out the medaka *tyr*, *oca2* and *pax6.1* genes using the msSaCas9 system

The medaka *tyr* genomic DNA contains six exons. The sgRNAs of R4445/ F4553 were designed in the fifth coding exon (Fig. 2a). Three days post-injection (dpi) of embryos with the Cas9 and sgRNAs, the absence of pigment from the eye (n=56/135) was observed (Fig. 2b). This was not observed in the wild type embryos (n=192). Moreover, the PCR and sequencing results demonstrated that both sgRNAs were functional, which was confirmed by sequencing in both sites (Figs 2c and 2d). In addition, both sequence mutations were found near two sgRNAs except for the deletion of more than 120 bp between the two sgRNAs (Fig. 2d). Notably, we also observed that the different mutation sequences occurred in the same embryo when we analyzed single embryos by sequencing (Fig. 2d, black arrows), meaning gene editing is a dynamic process.

To investigate the editing of more genes, we also tested the *oac2* gene, which is another important gene for pigmentation during eye development. Two sgRNAs, F9011 and F9254, were designed in exon 5 or exon 7 accordingly. Similarly, the pigmentation was partially lost in the injected embryos (Figs. 3a and 3b, n=40/41), and the mutations were confirmed in both sgRNAs (Fig. 3c).

The *pax6.1* gene, another master gene for eye development in medaka, was also tested. The sgRNAs were designed in exon 6. Similarly, ocular malformation of the eye (Figs 4a and 4b, n=23/73) was observed in the *pax6.1* sgRNA group at 5 dpi, and the mutations were confirmed by sequencing in the sgRNA (Figs 4c and 4d, R14135). Therefore, the SaCas9 system can be used effectively and easily to edit the medaka genome.

3.3 PAM is necessary for the mSaCas9 system

To test whether the PAM sequence of NNGRRT is necessary for gene editing, we also used an alternative PAM sequence of NNNNNN (NR4443/NR4475) (Figs 5a-5c). We also extended the spacer from 21 to 24 nt in the control group (R4414/R4468, 24 nt) (Figs 5a-5c). While no phenotype was detected in the NR group (Fig. 5c, NR4443/NR4475, n=0/39), the control group that was injected with R4414/R4468 (24 nt, n=29/51) showed a considerable difference in the eye (Fig. 5b). Moreover, the mutation sequences were confirmed in the mutant group but not in the NR group (Fig. 5c). Therefore, the PAM sequence NNGRRT is essential for gene editing, and the extended 24 nt spacer is also acceptable, as tested for the three genes above.

3.4 tRNA mediates functional sgRNA in the SaCas9 system

Generation of the functional sgRNA is an essential part of gene editing, which is always a challenge in divergent species. To test whether the sgRNA can function *in vivo* or *in vitro* by linking to the tRNA, which is an ideally and systematically self-processed cellular component, we also injected the tRNA-sgRNA mixed with Cas9. As in the embryos injected with the sgRNA mixture (Fig. 2a), the absence of pigment from the eye was observed in the tRNA-sgRNA (n=7/23) (Figs 6a and 6b) and tRNA-sgRNA-tRNA embryos (n=43/100) (Fig. 6b), indicating that tRNA mediates functional sgRNA in medaka embryos by RNA injection. The absence of pigment from the eye was also observed in the plasmid group (n=12/152, Fig. 6b), indicating that the tRNA-sgRNA-tRNA system is also functional following DNA injection. Sequencing also confirmed the mutation (Fig. 6c).

3.5 All-in-one promoter system to mediate gene editing by tRNA

To test whether the tRNA could also mediate the Cas9 protein and sgRNA stimulation, we inserted the tRNA between the SaCas9 and sgRNA, in which only the promoter CMV / T7 controls the expression of Cas9 and sgRNA together (Figs 7a and 7b). The RNAs were transcribed by T7 RNA polymerase and injected into embryos with or without the verified sgRNA (R4445). As expected, the absence of pigment from the eye was also observed both in the SaCas9-tRNA-sgRNA-tRNA embryos (mRNA without sgRNA, n=49/50) and SaCas9-tRNA-sgRNA-tRNA+sgRNA embryos (mRNA with gRNA, n=44/51) (Fig. 7b) and the mutations were also confirmed by sequencing (Fig. 7c). This indicates that tRNA mediates functional sgRNA and SaCas9 in medaka embryos following RNA injection. Therefore, the tRNA mediates the sgRNA function in the embryo following either RNA or DNA injection, either of which could potentially be used in the fish cells.

Unedited

3.6 Generation of the heritable mutants

After we observed the loss of pigmentation, the mutated embryos were raised to adult fish and homozygotes were produced following standard procedures. The homozygotes produced by SpCas9 were also used to hybridize with homozygotes produced by SaCas9. Compared with the black eye colour of wild type medaka, the eyes were red color in SpCas9 and SaCas9 strains, both in males and females (Figs 8a-8f). Consequently, hybridized albinos can also be produced, showing the red color in the eye and mutated sequence in different strains (Fig. 8g). In addition, all mutant strains were maintained stably for more than eight generations in the lab.

4 Discussion

The gene editing system is the most powerful tool developed during the last decade to analyze gene function and generate specific mutants. Compared to the well-established SpCas9 system that is used in different species including mammals, teleostean fish, and bacteria, in this study we extended the SaCas9 system and examined editing efficiency in medaka fish.

Firstly, the smaller SaCas9 is functional in the medaka genome. SaCas9 (3.3 kb) is almost 25% smaller than SpCas9 (nearly 4.3 kb). This facilitates cloning, transcription and transfection for different purposes. Researchers have demonstrated the ability to use the SaCas9 system to edit genomes efficiently and have applied it

to mammals using AAV viruses for gene editing in different models (Li et al., 2018; Zhang et al., 2016). In this study, we successfully used a codon-optimized SaCas9 system for gene editing of medaka. Moreover, the RNA transcription or DNA vector of a particular gene sgRNA can be obtained easily by simple PCR or one-step cloning.

Secondly, the SaCas9 can mediate gene editing in both sgRNAs. By sequencing, we found that gene editing occurred in single sgRNA or both sgRNAs. Most importantly, there were few bp mutations near both sgRNAs, except for the deletion of a whole fragment between the two sgRNAs, meaning the mutations had occurred simultaneously in some cases. We also found that different mutation types can be detected in a single embryo, indicating that gene editing can occur in different cells during embryonic cleavage, possibly due to the high concentration of injected Cas9 and sgRNAs. For example, gene editing happened in one, two, or four cells, resulting in the different mutant types. Consequently, different mutants can be obtained from only a few (such as ten to twenty) injected embryos if the sgRNA is suitable, which reduces the investment needed to screen the large number of mutants in subsequent steps.

Thirdly, the PAM sequence NNGRRT is also important for gene editing efficiency, as confirmed in this study (Brooks and Gaj, 2018; Friedland et al., 2015; Ran et al., 2015; Xie et al., 2018). No mutation could be obtained by changing the PAM sequence of NNGRRT to a random sequence of NNNNNN. In addition, extending the spacer from 21 to 24 nt did not affect its function. Moreover, the sgRNA was still functional either put back of tRNA or inserted between two tRNAs, which is important for enabling vector cloning of sgRNA expression by conventional promoters such as the Cytomegalovirus promoter (Pan et al., 2022). Most important, the transcribed RNA from one promoter, such as T7, is also functional for SaCas9 translation and sgRNA processing, and the two parts are functional, as verified in this study. Therefore, the combination of SaCas9/tRNA-sgRNA is suitable for gene editing of medaka embryos.

Lastly, stable and heritable mutants can be readily generated. We obtained *tyr*$^{-/-}$ albino strains using SpCas9 (Fang et al., 2018), SaCas9, or a hybrid of both systems, suggesting that SaCas9 may be an easy and acceptable system to generate other strains with heritable mutations.

Taken together, the SaCas9 editing system has been optimized and verified in medaka to generate mutants and could also be applied to other fish cell lines or other teleosts. Ideally, a minimal cassette for SaCas9-sgRNA expression will be desired for robot gene mutation in the future.

Unedited

Data availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Acknowledgments

This study was supported by the National Natural Science Foundation of China (32273127 & 31771648 & 31672653), the Scientific Research Foundation of Jimei University (No. ZQ2020003).

Author contributions

Yuewen JIANG performed the experiment, analyzed experimental data, wrote the original draft; Qihua PAN, Zhi WANG, Ke LU, and Bilin XIA participated in part of the experiment and edited the manuscript; Tiansheng CHEN acquired research funding, designed and supervised the experiment, analyzed experimental data, wrote and edited the manuscript. All authors read and approved the final manuscript and, therefore, had full access to all the data in the study and take responsibility for the integrity and security of the data.

Compliance with ethics guidelines

Yuewen JIANG, Qihua PAN, Zhi WANG, Ke Lu, Bilin XIA, and Tiansheng CHEN declare that they have no conflict of interest.

All institutional and national guidelines for the care and use of laboratory animals were followed.

References

Balboa D, Weltner J, Novik Y, et al., 2017. Generation of a SOX2 reporter human induced pluripotent stem cell line using

CRISPR/SaCas9. *Stem Cell Res*, 22:16-19.
https://doi.org/10.1016/j.scr.2017.05.005

Brooks AK, Gaj T, 2018. Innovations in CRISPR technology. *Curr Opin Biotechnol*, 52:95-101.
https://doi.org/10.1016/j.copbio.2018.03.007

Chen TS, Cavari B, Schartl M, et al., 2017. Identification and expression of conserved and novel RNA variants of medaka *pax6b* gene. *J Exp Zool Part B*, 328(5):412-422.
https://doi.org/10.1002/jez.b.22742

Dickinson DJ, Ward JD, Reiner DJ, et al., 2013. Engineering the Caenorhabditis elegans genome using Cas9-triggered homologous recombination. *Nat Methods*, 10(10):1028-1037.
https://doi.org/10.1038/Nmeth.2641

Dong FP, Xie KB, Chen YY, et al., 2017. Polycistronic tRNA and CRISPR guide-RNA enables highly efficient multiplexed genome engineering in human cells. *Biochem Bioph Res Co*, 482(4):889-895.
https://doi.org/10.1016/j.bbrc.2016.11.129

Fang J, Chen TS, Pan QH, et al., 2018. Generation of albino medaka (*Oryzias latipes*) by CRISPR/Cas9. *J Exp Zool Part B*, 330(4):242-246.
https://doi.org/10.1002/jez.b.22808

Feng Y, Chen C, Han YX, et al., 2016. Expanding CRISPR/Cas9 genome editing capacity in zebrafish using SaCas9. *G3-Genes Genom Genet*, 6(8):2517-2521.
https://doi.org/10.1534/g3.116.031914

Friedland AE, Baral R, Singhal P, et al., 2015. Characterization of Staphylococcus aureus Cas9: a smaller Cas9 for all-in-one adeno-associated virus delivery and paired nickase applications. *Genome Biol*, 16:257.
https://doi.org/10.1186/S13059-015-0817-8

Gratz SJ, Cummings AM, Nguyen JN, et al., 2013. Genome engineering of drosophila with the CRISPR RNA-guided Cas9 nuclease. *Genetics*, 194(4):1029-1035.
https://doi.org/10.1534/genetics.113.152710

Hu ZY, Wang S, Zhang CD, et al., 2020. A compact Cas9 ortholog from Staphylococcus Auricularis (SauriCas9) expands the DNA targeting scope. *Plos Biol*, 18(3):e3000686.
https://doi.org/10.1371/journal.pbio.3000686

Hwang WY, Fu YF, Reyon D, et al., 2013. Efficient genome editing in zebrafish using a CRISPR-Cas system. *Nat Biotechnol*, 31(3):227-229.
https://doi.org/10.1038/nbt.2501

Jinek M, Chylinski K, Fonfara I, et al., 2012. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science*, 337(6096):816-821.
https://doi.org/10.1126/science.1225829

Katayama S, Sato K, Nakazawa T, 2020. In vivo and in vitro knockout system labelled using fluorescent protein via microhomology-mediated end joining. *Life Sci Alliance*, 3(1):e201900528.
https://doi.org/10.26508/lsa.201900528

Kleinstiver BP, Prew MS, Tsai SQ, et al., 2015. Engineered CRISPR-Cas9 nucleases with altered PAM specificities. *Nat Biotechnol*, 523(7561):481-497.
https://doi.org/10.1038/nature14592

Li H, Sheng C, Liu H, et al., 2018. Inhibition of HBV Expression in HBV Transgenic Mice Using AAV-Delivered CRISPR-SaCas9. *Front Immunol*. 9:2080.
https://doi.org/10.3389/fimmu.2018.02080

Ma CF, Zhu CZ, Zheng M, et al., 2019. CRISPR/Cas9-mediated multiple gene editing in Brassica oleracea var. capitata using the endogenous tRNA-processing system. *Hortic Res*. 6:20.
https://doi.org/10.1038/s41438-018-0107-1

Makarova KS, Aravind L, Wolf YI, et al., 2011a. Unification of Cas protein families and a simple scenario for the origin and evolution of CRISPR-Cas systems. *Biol Direct*, 6:38.
https://doi.org/10.1186/1745-6150-6-38

Makarova KS, Haft DH, Barrangou R, et al., 2011b. Evolution and classification of the CRISPR-Cas systems. *Nat Rev Microbiol*, 9(6):467-477.
https://doi.org/10.1038/nrmicro2577

Makarova KS, Wolf YI, Alkhnbashi OS, et al., 2015. An updated evolutionary classification of CRISPR-Cas systems. *Nat Rev Microbiol*, 13(11):722-736.
https://doi.org/10.1038/nrmicro3569

Mefferd AL, Kornepati AVR, Bogerd HP, et al., 2015. Expression of CRISPR/Cas single guide RNAs using small tRNA promoters.

Unedited

Rna, 21(9):1683-1689.
https://doi.org/10.1261/rna.051631.115

Mojica FJM, Diez-Villasenor C, Garcia-Martinez J, et al., 2009. Short motif sequences determine the targets of the prokaryotic CRISPR defence system. *Microbiol-Sgm*, 155:733-740.
https://doi.org/10.1099/mic.0.023960-0

Nakaar V, Dare AO, Hong D, et al., 1994. Upstream tRNA genes are essential for expression of small nuclear and cytoplasmic RNA genes in trypanosomes. *Mol Cell Biol*, 14(10):6736-6742.
https://doi.org/10.1128/mcb.14.10.6736-6742.1994.

Numamoto M, Maekawa H, Kaneko Y, 2017. Efficient genome editing by CRISPR/Cas9 with a tRNA-sgRNA fusion in the methylotrophic yeast Ogataea polymorpha. *J Biosci Bioeng*, 124(5):487-492.
https://doi.org/10.1016/j.jbiosc.2017.06.001

Pan Q, Luo J, Jiang Y, et al., 2022. Efficient gene editing in a medaka (*Oryzias latipes*) cell line and embryos by SpCas9/tRNA-gRNA. *J Zhejiang Univ Sci B*, 23(1):74-83.
https://doi.org/10.1631/jzus.B2100343

Pan Q, Lu K, Luo J, et al., 2023a. Japanese medaka Olpax6.1 mutant as a potential model for spondylo-ocular syndrome. *Funct Integr Genomics*, 23(2):168.
https://doi.org/10.1007/s10142-023-01090-4

Pan Q, Luo J, Jiang Y, et al., 2023b. Medaka (Oryzias latipes) Olpax6.2 acquires maternal inheritance and germ cells expression, but functionally degenerate in the eye. *Gene*, 872:147439.
https://doi.org/10.1016/j.gene.2023.147439

Port F, Bullock SL, 2016. Expansion of the CRISPR toolbox in an animal with tRNA-flanked Cas9 and Cpf1 gRNA. *Biorxiv Preprint*. online.
https://doi.org/10.1101/046417

Qi W, Zhu T, Tian Z, et al., 2016. High-efficiency CRISPR/Cas9 multiplex gene editing using the glycine tRNA-processing system-based strategy in maize. *Bmc Biotechnol*, 16(1):58.
https://doi.org/10.1186/s12896-016-0289-2

Ran FA, Cong L, Yan WX, et al., 2015. In vivo genome editing using Staphylococcus aureus Cas9. *Nature*, 520(7546):186-191.
https://doi.org/10.1038/nature14299

Shiraki T, Kawakami K, 2018. A tRNA-based multiplex sgRNA expression system in zebrafish and its application to generation of transgenic albino fish. *Sci Rep*, 8(1):13366.
https://doi.org/10.1038/s41598-018-31476-5

Swiech L, Heidenreich M, Banerjee A, et al., 2015. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. *Nat Biotechnol*, 33(1):102-106.
https://doi.org/10.1038/nbt.3055

Wang LL, Yang Y, Breton C, et al., 2020. A mutation-independent CRISPR-Cas9–mediated gene targeting approach to treat a murine model of ornithine transcarbamylase deficiency. *Sci Adv*, 6(7):eaax5701.
https://doi.org/10.1126/sciadv.aax5701

Wang Q, Liu S, Liu Z, et al., 2018. Genome scale screening identification of SaCas9/gRNAs for targeting HIV-1 provirus and suppression of HIV-1 infection. *Virus Res*, 250:21-30.
https://doi.org/10.1016/j.virusres.2018.04.002

Wiedenheft B, Sternberg SH, Doudna JA, 2012. RNA-guided genetic silencing systems in bacteria and archaea. *Nat Biotechnol*, 482(7385):331-338.
https://doi.org/10.1038/nature10886

Wu H, Liu Q, Shi H, et al., 2018. Engineering CRISPR/Cpf1 with tRNA promotes genome editing capability in mammalian systems. *Cell Mol Life Sci*, 75(19):3593-3607.
https://doi.org/10.1007/s00018-018-2810-3

Xie H, Tang L, He X, et al., 2018. SaCas9 Requires 5'-NNGRRT-3' PAM for Sufficient Cleavage and Possesses Higher Cleavage Activity than SpCas9 or FnCpf1 in Human Cells. *Biotechnol J*, 13(3):e1800080.
https://doi.org/10.1002/biot.201800080

Xie KB, Minkenberg B, Yang YN, 2015. Boosting CRISPR/Cas9 multiplex editing capability with the endogenous tRNA-processing system. *P Natl Acad Sci Usa*, 112(11):3570-3575.
https://doi.org/10.1073/pnas.1420294112

Yang Z, Fu Y, Zhao J, et al., 2022. Superior Fidelity and Distinct Editing Outcomes of SaCas9 Compared to SpCas9 in Genome Editing. *Genom Proteom Bioinf*, online.
https://doi.org/10.1016/j.gpb.2022.12.003

Zhang X, Liang P, Ding C, et al., 2016. Efficient Production of Gene-Modified Mice using Staphylococcus aureus Cas9. *Sci Rep*,

Unedited

6(1):32565.
https://doi.org/10.1038/srep32565
Zhang YP, Wang J, Wang ZB, et al., 2019. A gRNA-tRNA array for CRISPR-Cas9 based rapid multiplexed genome editing in Saccharomyces cerevisiae. *Nat Commun*, 10:1053.
https://doi.org/10.1038/s41467-019-09005-3

Unedited

Figure legends:



Unedited

Figure 1. Synthesis of mSaCas9 DNA, sgRNA scaffold and sgRNA. a) Map of SaCas9 expression vector. SaCas9 uses NNGR(A/T) RT as the PAM sequence, and its length is smaller than that of SpCas9. b) Primers were designed and annealed to synthesize mSaCas9 sgRNA scaffold, and spacers carrying the T7 promoter were synthesized using mSaCas9 sgRNA scaffold as a template. c) Construction of the tRNA-sgRNA expression vector. The target fragment sgRNA was ligated into the linearized vector pCS2-tRNA by infusion to obtain a recombinant plasmid pCS2+tRNA-tyr-sgRNA including a fragment of tRNA and sgRNA. d) Construction of the tRNA-sgRNA-tRNA expression vector. The target fragment in-RNA was ligated into the linearized vector pCS2+tRNA-tyr-gRNA by infusion to obtain a recombinant plasmid pCS2+tRNA-tyr-gRNA+tRNA including a fragment of two tRNA and sgRNA.



Figure 2. Analysis of R4445 and F4553 knockout in *tyr* gene. a) The sequences of R4445 and F4553 are underlined in blue while PAM sequences are underlined in green. b) A significant loss of pigmentation was observed in the mutation group (MT: 56/135) compared to wild type (WT, 0/192). Scale bar = 200 μm. c) The PCR product from heterozygous mutant embryos (1, 2) and wild type embryos (WT) were treated with T7 endonuclease (T7EI). d) Monoclonal sequencing of different bands. There were several base mutations in the single or dual sgRNA knockout sites.



Unedited

Figure 3. Analysis of F9011 and F9254 knockout in *oca2* gene. a) The sequences of F9011 and F9254 are underlined in blue, while PAM sequences are underlined in green. b) Compared with wild type embryos (WT, N=192), the heterozygous mutations showed a significant pigment deletion (MT, N=40/41). Scale bar = 200 μm. c) Monoclonal sequencing of PCR fragments. The PCR products from mutant (MT1/MT2) and wild type (WT) embryos were treated with T7 endonuclease (T7EI). Different types of mutations were found in the same embryo.



Figure 4. Analysis of R14069 and R14135 knockout results in *pax6.1*. a) The sequences of R14069 and R14135 are underlined in blue while PAM sequences are underlined in green. b) Compared with wild type embryos (WT, N=192), the heterozygous mutant embryos showed significant ocular malformation (MT, N=23/73). Scale bar = 200 μm. c) Monoclonal sequencing of PCR fragments. The PCR products from mutant (MT1) and wild type (WT) embryos were treated with T7 endonuclease (T7EI). There were several types of mutations only in the R14135 knockout site.

Unedited



Unedited

Figure 5. Analysis of R4414+R4468 and NR4443+NR4475 knockout results in *tyr* gene. a). The sequences of R4414 and R4468 are underlined in blue, and those of NR4443 and NR4475 are underlined in red. PAM sequences are underlined in green. b) The heterozygous mutants showed significant pigment deletion in the R4414+R4468 group (R, N=29/51) but not in the NR4443+NR4475 group (NR, N=0/39). Scale bar = 200 μm. c) Monoclonal sequencing of PCR products. The PCR products from mutations (R), NR and wild type (WT) were treated with T7 endonuclease (T7EI). There were several base mutations in the sgRNA knockout sites in the R group but not in the NR or WT groups.



Figure 6. Analysis of tRNA-sgRNA in RNA or DNA content in tyr-sgRNA-tRNA knockout results. a) The sequence of R4445 is underlined in blue while that of the PAM is underlined in green. b) The heterozygous mutants showed a significant pigment deletion in SP6-pCS2+tRNA-tyr-sgRNA (N=7/23), SP6-pCS2+tRNA-tyr-sgRNA-tRNA (N=43/100), and pCS2+tRNA-mSatyr-sgRNA+tRNA DNA groups (N=12/152). Scale bar = 200 μm. c) Monoclonal sequencing of PCR products. The PCR products from mutants and wild type were treated with T7 endonuclease (T7EI). There were several types of mutations in the R4445 knockout site in different groups.

Unedited



Unedited

Figure 7. mSaCas9-tRNA-sgRNA in tyr gene knockout results. a) The sequence of R4445 is underlined in blue while that of the PAM is underlined in green. b) An illustration of the all-in-one vector CMV-Cas9-tRNA-sgRNA-tRNA. The heterozygous mutants showed a significant pigment deletion in the mSaCas9-tRNA-tyr sgRNA-tRNA (N=44/51) and mSaCas9-tRNA-tyr gRNA-tRNA+tyr sgRNA groups (N=49/50). Scale bar = 200 μm. c) The PCR products from mutants and wild type were treated with T7 endonuclease (T7EI), and multiple peaks were detected in the sequencing of the PCR products.



Figure 8. Adult fish of the *tyr* mutant generated by the SaCas9 or SpCas9 system. a) Wild-type male medaka (♂). b) Wild-type female medaka (♀). c) The male homozygote of the SaCas9 knockout (♂). d) The female homozygote of the SaCas9 knockout (♀). e) The male homozygote of the SpCas9 knockout (♂). f) The female homozygote of the SpCas9 knockout (♀). Scale bar = 500 μm. g) Monoclonal sequencing of PCR products in wild type and homozygous medaka. There were mutations in different sgRNAs regions in the SpCas9 and SaCas9 strains.

Unedited

Tables:

Table 1. Primers used in the experiment

	Sequence (5'-3')
cRNA F	GTTTTAGTACTCTGGAAACAGAATCTACTAAAACAAGGCAAAATGCCGTG
cRNA R	AAAAATCTCGCCAACAAGTTGACGAGATAAACACGGCATTTTGCCTTG
in-gRNA F	TCGATTCCCGGCTGGTGCAGGGTCTTCGAGAAGACCTGTTTTAGTACTCTGGAAACAG
in-tRNA F	GTTGGCGAGATTTTTCTCGAGAACAAAGCACCAGTGGTCTAGTG
in-tRNA R	TATCATGTCTGGATCTACGTATGCACCAGCCGGGAATCGAAC
T7-R4445-cRNA	TAATACGACTCACTATAGGaattgtggcgatcaaagcaccGTTTTAGTACTCTGGAAAC
T7-F4553-cRNA	TAATACGACTCACTATAGGctgttgcagagcagttcagaaGTTTTAGTACTCTGGAAAC
T7-R4414-cRNA	TAATACGACTCACTATAGGgatctgctgggcttgctgaaggtaGTTTTAGTACTCTGGA
T7-R4468-cRNA	TAATACGACTCACTATAGGaacaattgtggcgatcaaagcaccGTTTTAGTACTCTGGA
T7-NR4443-cRNA	TAATACGACTCACTATAGGaggatcccggcccccaggagccaGTTTTAGTACTCTGGA
T7-NR4475-cRNA	TAATACGACTCACTATAGGccgcggcaacaattgtggcgatcaGTTTTAGTACTCTGGA
T7-R14069-cRNA	TAATACGACTCACTATAGGcgcgattttggcgaccacctcGTTTTAGTACTCTGGAAAC
T7-R14135-cRNA	TAATACGACTCACTATAGGcccctccgacaggagcctgtcGTTTTAGTACTCTGGAAAC

T7-F9011-cRNA	TAATACGACTCACTATAGGtccagaccgagacaacccctgGTTTTAGTACTCTGGAAAC
T7-F9254-cRNA	TAATACGACTCACTATAGGacatgctgaacggagtctccaGTTTTAGTACTCTGGAAAC
Reverse	CTATAGTTCTAGAGGCTCGAGAAAAATCTCGCCAACAAGTTG
tyr seqF	ATGACGGCTACTACATGGTGC
tyr seqR	ATGACGGCTACTACATGGTGC
pax6.1 seqF	CAGCTTGGTGGCGTGTTTGTTA
pax6.1 seqR	GTCACATGCACCTTCCCTCCTC
oca2 DF	TGCAAACAGGATCGAGGGTT
oca2 DR	CTGCTTTACTTCGGTTTGGTGT

Table 2. Contents of injections used in the experiments

	Injection content （Gene; DNA/RNA）	Injection number	Survival number	Mutation number	Mutation rate
WT	NA	0	192	0	0.0%
Group 1	R4445 + F4553 sgRNA （*tyr*; RNA）	194	135	56	41.5%
Group 2	R14069+R14135 sgRNA （*pax6.1*; RNA）	81	73	23	31.5%
Group 3	R4414+R4468 sgRNA （*tyr*; RNA）	92	51	29	56.9%
Group 4	NR4443+NR4475 sgRNA （*tyr*; RNA）	50	39	0	0.0%
Group 5	SP6-pCS2+tRNA-mSatyr-sgRNA （*tyr*; RNA）	30	23	7	30.4%
Group 6	SP6-pCS2+tRNA-mSatyr-sgRNA+tRNA （*tyr*; RNA）	124	100	43	43.0%
Group 7	pCS2+tRNA-tyr R4445 (*tyr*; DNA)	239	129	9	7.0%
Group 8	pCS2+tRNA-tyr-sgRNA+tRNA (*tyr*; DNA)	216	152	12	7.9%
Group 9	F9011 + F9254 （*oca2*, RNA）	50	41	40	98%
Group 10	mSaCas9-tRNA-tyr sgRNA-tRNA (*tyr*, RNA)	52	50	49	98%
Group 11	mSaCas9-tRNA-tyr sgRNA-tRNA+tyr sgRNA (*tyr*, RNA)	54	51	44	86.3%

F: forward direction; R: reverse direction

Unedited

Supplementary information:

1. Sequence of pC322mSaCas9-(CMV-T7-SaCas9-PolyA)

GACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAG-
TTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGG-
TAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGAC-
GTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGACTATTTAC-
GGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGAC-
GTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCC-
TACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAG-
TACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATT-
GACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCG-
TAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAA-
GCAGAGCTCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTATCGAAATTAATAC-
GACTCACTATAGGGAGACCCAAGCTGGCTAGCCTCGAGATGGCCCCCAAGAAGAAGAG-
GAAAGTGGGCATCCACGGAGTGCCAGCCGCTAAGCGCAACTACATCCTGGGCCTGGACATCG-
GAATCACCTCCGTGGGATACGGCATCATCGACTACGAGACCCGCGACGTGATCGACGCTG-
GAGTGAGGCTGTTCAAAGAGGCCAACGTGGAGAACAACGAGGGCAGGAGAAGCAAGAGAG-
GAGCTCGCAGGCTGAAGAGACGCAGGAGACACAGAATCCAGCGCGTGAAGAA-
GCTGCTGTTCGACTACAACCTGCTGACCGACCACTCCGAGCTGAGCGGCATCAACCCCTAC-
GAGGCCAGGGTGAAGGGACTGTCCCAGAAGCTGAGCGAGGAAGAGTTTTCCGCCGCTCTGCTG-
CACCTGGCTAAGCGCAGGGGCGTGCACAACGTGAACGAGGTGGAAGAGGACACCGGAAAC-
GAGCTGAGCACCAAGGAGCAGATCTCCCGCAACAGCAAGGCCCTGGAGGAGAAGTAC-
GTGGCTGAGCTGCAGCTGGAGAGGCTGAAGAAGGACGGCGAGGTGCGCG-
GATCCATCAACAGGTTCAAGACCAGCGACTACGTGAAAGAGGCCAAGCAGCTGCTGAAGGTG-
CAGAAGGCTTACCACCAGCTGGACCAGTCCTTTATCGACACCTACATCGACCTGCTGGAGAC-
CAGACGCACCTACTACGAGGGACCAGGAGAGGGAAGCCCATTCG-
GATGGAAGGACATCAAGGAGTGGTACGAGATGCTGATGGGACACTGCACCTACTTTCCTGAG-
GAGCTGAGATCCGTGAAGTACGCCTACAACGCTGACCTGTACAACGCCCTGAACGAC-
CTGAACAACCTGGTGATCACCCGCGACGAGAACGAGAAGCTGGAGTACTACGA-
GAAGTTCCAGATCATCGAGAACGTGTTTAAGCAGAAGAAGAAGCCCACCCTGAA-
GCAGATCGCCAAGGAGATCCTGGTTAACGAAGAGGACATCAAGGGCTACAGGGTGACCAG-
CACCGGAAAGCCTGAGTTCACCAACCTGAAGGTGTACCACGACATCAAGGACATCACCGCTA-
GAAAGGAGATCATCGAGAACGCCGAGCTGCTGGACCAGATCGCTAAGATCCTGACCATCTAC-
CAGAGCTCCGAGGACATCCAGGAAGAGCTGACCAACCTGAACTCCGAGCTGACCCAGGAAGA-
GATCGAGCAGATCAGCAACCTGAAGGGCTACACCGGAACCCACAAC-
CTGTCCCTGAAGGCCATCAACCTGATCCTGGACGAGCTGTGGCACACCAACGACAAC-
CAGATCGCTATCTTTAACAGACTGAAGCTGGTGCCTAAGAAGGTGGACCTGTCCCAG-
CAGAAGGAGATCCCAACCACCCTGGTGGACGACTTCATCCTGAGCCCCGTGGTGAAGA-
GATCCTTTATCCAGAGCATCAAGGTGATCAACGCCATCATCAAGAAGTACGGCCTGCCAAAC-
GACATCATCATCGAGCTGGCCAGGGAGAAGAACTCCAAGGACGCTCAGAAGATGATCAACGA-
GATGCAGAAGCGCAACAGGCAGACCAACGAGAGAATCGAGGAGATCATCCGCACCACCGG-
CAAGGAGAACGCCAAGTACCTGATCGAGAAGATCAAGCTGCACGACATGCAG-
GAAGGAAAATGCCTGTACAGCCTGGAGGCTATCCCTCTGGAGGAC-
CTGCTGAACAACCCATTCAACTACGAGGTGGACCACATCATCCCAC-
GCTCCGTGAGCTTCGACAACTCCTTTAACAACAAGGTGCTGGTGAAGCAGGAAGAGAACAG-
CAAGAAGGGAAACAGGACCCCCTTCCAGTACCTGAGCTCCAGCGACTCCAAGATCAGCTACGA-
GACCTTTAAGAAGCACATCCTGAACCTGGCCAAGGGCAAGGGAAGAATCTCCAAGACCAA-
GAAGGAGTACCTGCTGGAGGAGCGCGACATCAACAGGTTCAGCGTG-
CAGAAGGACTTTATCAACCGCAACCTGGTGGACACCAGATACGC-
TACCCGCGGCCTGATGAACCTGCTGAGATCCTACTTCAGAGTGAACAACCTGGAC-
GTGAAGGTGAAGTCCATCAACGGAGGCTTCACCAGCTTTCTGAGGAGAAAGTGGAAGTTTAA-
GAAGGAGAGAAACAAGGGATACAAGCACCACGCCGAGGACGCTCTGATCATCGCCAAC-
GCTGACTTCATCTTTAAGGAGTGGAAGAAGCTGGACAAGGCCAAGAAGGTGATGGAGAAC-
CAGATGTTCGAGGAGAAGCAGGCTGAGAGCATGCCAGAGATCGAGACCGAGCAGGAG-

Unedited

TACAAGGAGATCTTCATCACCCCCCACCAGATCAAGCACATCAAGGACTTTAAGGAC-
TACAAGTACTCCCACAGGGTGGACAAGAAGCCAAACAGAGAGCTGATCAACGACACCCTG-
TACAGCACCAGGAAGGACGACAAGGGCAACACCCTGATCGTGAACAACCTGAACGGACTGTAC-
GACAAGGACAACGACAAGCTGAAGAAGCTGATCAACAAGTCCCCCGAGAAGCTGCTGATGTAC-
CACCACGACCCTCAGACCTACCAGAAGCTGAAGCTGATCATGGAGCAGTACGGCGACGAGAA-
GAACCCTCTGTACAAGTACTACGAGGAGACCGGAAACTACCTGACCAAGTACAGCAA-
GAAGGACAACGGCCCAGTGATCAAGAAGATCAAGTACTACGGAAACAAGCTGAACGCCCAC-
CTGGACATCACCGACGACTACCCCAACTCCAGGAACAAGGTGGTGAAGCTGAGCCTGAAGCCT-
TACAGATTCGACGTGTACCTGGACAACGGAGTGTACAAGTTTGTGACCGTGAAGAACCTG-
GACGTGATCAAGAAGGAGAACTACTACGAGGTGAACTCCAAGTGCTACGAGGAAGCCAAGAA-
GCTGAAGAAGATCTCCAACCAGGCCGAGTTCATCGCTAGCTTTTACAACAACGACCTGATCAA-
GATCAACGGCGAGCTGTACAGAGTGATCGGAGTGAACAACGACCTGCTGAACCG-
CATCGAGGTGAACATGATCGACATCACCTACAGGGAGTACCTGGAGAACATGAACGATAA-
GAGGCCCCCTAGAATCATCAAGACCATCGCCAGCAAGACCCAGAGCATTAAGAAGTACAG-
CACAGACATTCTGGGCAACCTGTATGAAGTGAAATCTAAGAA-
GCACCCTCAGATCATCAAAAAGGGCAAAAGGCCGGCGGCCAC-
GAAAAAGGCCGGCCAGGCAAAAAAGAAAAAGGGATCCTACCCATACGATGTTCCAGATTAC-
GCTTACCCATACGATGTTCCAGATTACGCTTACCCATACGATGTTCCAGATTACGTTTAAAC-
GCGGCCGCCCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTT-
GCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAA-
TAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTC-
TATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAA-
TAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGG

2. Sequence of T7-spacer-sgRNA scaffold

TAATACGACTCACTATAGGAATTGTGGCGATCAAAGCACCGTTTTAGTACTCTG-
GAAACAGAATCTACTAAAACAAGGCAAAATGCCGTGTTTATCTCGTCAACTTGTTGGCGAGATTTTT

3. Sequence of pCS2-tRNA-*Bbs* I-*Bbs* I-NN—*Xho* I-*NN*

AACAAAGCACCAGTGGTCTAGTGGTAGAATAGTACCCTGCCACGG-
TACAGACCCGGGTTCGATTCCCGGCTGGTGCAGGGTCTTCGAGAAGACCT-NN-CTCGAG-NN

4. Sequence of pCS2-tRNA-sgRNA-(CMV-SP6-tRNA-spacer-sgRNA scaffold-T7-PolyA)

GTCGACCATAGCCAATTCAATATGGCGTATATGGACTCATGCCAATTCAATATGGTGGATCTG-
GACCTGTGCCAATTCAATATGGCGTATATGGACTCGTGCCAATTCAATATGGTGGATCTG-
GACCCCAGCCAATTCAATATGGCGGACTTGGCACCATGCCAATTCAATATGGCGGACTTGG-
CACTGTGCCAACTGGGGAGGGGTCTACTTGGCACGGTGCCAAGTTTGAGGAGGGGTCTT-
GGCCCTGTGCCAAGTCCGCCATATTGAATTGGCATGGTGCCAATAATGGCGGCCATATTGGC-
TATATGCCAGGATCAATATATAGGCAATATCCAATATGGCCCTATGCCAATATGGC-
TATTGGCCAGGTTCAA-
TACTATGTATTGGCCCTATGCCATATAGTATTCCATATATGGGTTTTCCTATTGACGTAGA-
TAGCCCCTCCCAATGGGCGGTCCCATATACCATATATGGGGCTTCCTAATACCGCCCA-
TAGCCACTCCCCCATTGACGTCAATGGTCTCTATATATGGTCTTTCCTATTGACGTCAT-
ATGGGCGGTCCTATTGACGTATATGGCGCCTCCCCCATTGACGTCAATTACGG-
TAAATGGCCCGCCTGGCTCAATGCCCATTGACGTCAATAGGACCACCCACCATTGAC-
GTCAATGGGATGGCTCATTGCCCATTCATATCCGTTCTCACGCCCCCTATTGAC-
GTCAATGACGGTAAATGGCCCACTTGGCAGTACATCAATATCTATTAATAGTAACTTGG-
CAAGTACATTACTATTGGAAGGACGCCAGGGTACATTGGCAGTACTCCCATTGAC-
GTCAATGGCGGTAAATGGCCCGCGATGGCTGCCAAGTACATCCCCATTGACGTCAATGGG-
GAGGGGCAATGACGCAAATGGGCGTTCCATTGACGTAAATGGGCGGTAGGCGTGCCTAATGG-
GAGGTCTATATAAGCAATGCTCGTTTAGGGAACCGCCATTCTGCCTGGGGACGTCGGAGCAA-
GCTTGATTTAGGTGACACTATAGAATACAAGCTACTTGTTCTTTTTGCAGGATCCCATCGAT-
TCGAATTCAACAAAGCACCAGTGGTCTAGTGGTAGAATAGTACCCTGCCACGG-

Unedited

TACAGACCCGGGTTCGATTCCCGGCTGGTGCAAATTGTGGCGATCAAAGCACCGTTTTAG-
TACTCTGGAAACAGAATCTACTAAAACAAGGCAAAATGCCGTGTTTATCTCGTCAACTTGTT-
GGCGAGATTTTTCTCGAGCCTCTAGAACTATAGTGAGTCGTATTACGTAGATCCAGACATGA-
TAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAG-
TGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAA-
GCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGG-
GAGGTGTGGGAGGTTTTTA

5. Sequence of pCS2-tRNA-sgRNA-tRNA-(CMV-SP6-tRNA-spacer-sgRNA scaffold-tRNA- PolyA)

GTCGACCATAGCCAATTCAATATGGCGTATATGGACTCATGCCAATTCAATATGGTGGATCTG-
GACCTGTGCCAATTCAATATGGCGTATATGGACTCGTGCCAATTCAATATGGTGGATCTG-
GACCCCAGCCAATTCAATATGGCGGACTTGGCACCATGCCAATTCAATATGGCGGACTTGG-
CACTGTGCCAACTGGGGAGGGGTCTACTTGGCACGGTGCCAAGTTTGAGGAGGGGTCTT-
GGCCCTGTGCCAAGTCCGCCATATTGAATTGGCATGGTGCCAATAATGGCGGCCATATTGGC-
TATATGCCAGGATCAATATATAGGCAATATCCAATATGGCCCTATGCCAATATGGC-
TATTGGCCCAGGTTCAA-
TACTATGTATTGGCCCTATGCCATATAGTATTCCATATATGGGTTTTCCTATTGACGTAGA-
TAGCCCCTCCCAATGGGCGGTCCCATATACCATATATGGGGCTTCCTAATACCGCCCA-
TAGCCACTCCCCCATTGACGTCAATGGTCTCTATATATGGTCTTTCCTATTGACGTCAT-
ATGGGCGGTCCTATTGACGTATATGGCGCCTCCCCCATTGACGTCAATTACGG-
TAAATGGCCCGCCTGGCTCAATGCCCATTGACGTCAATAGGACCACCCACCATTGAC-
GTCAATGGGATGGCTCATTGCCCATTCATATCCGTTCTCACGCCCCCTATTGAC-
GTCAATGACGGTAAATGGCCCACTTGGCAGTACATCAATATCTATTAATAGTAACTTGG-
CAAGTACATTACTATTGGAAGGACGCCAGGGTACATTGGCAGTACTCCCATTGAC-
GTCAATGGCGGTAAATGGCCCGCGATGGCTGCCAAGTACATCCCCATTGACGTCAATGGG-
GAGGGGCAATGACGCAAATGGGCGTTCCATTGACGTAAATGGGCGGTAGGCGTGCCTAATGG-
GAGGTCTATATAAGCAATGCTCGTTTAGGGAACCGCCATTCTGCCTGGGGACGTCGGAGCAA-
GCTTGATTTAGGTGACACTATAGAATACAAGCTACTTGTTCTTTTTGCAGGATCCCATCGAT-
TCGAATTCAACAAAGCACCAGTGGTCTAGTGGTAGAATAGTACCCTGCCACGG-
TACAGACCCGGGTTCGATTCCCGGCTGGTGCAAATTGTGGCGATCAAAGCACCGTTTTAG-
TACTCTGGAAACAGAATCTACTAAAACAAGGCAAAATGCCGTGTTTATCTCGTCAACTTGTT-
GGCGAGATTTTTCTCGAGAACAAAGCACCAGTGGTCTAGTGGTAGAATAGTACCCTGCCACGG-
TACAGACCCGGGTTCGATTCCCGGCTGGTGCATACGTAGATCCAGACATGATAAGATACATT-
GATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTT-
GTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAA-
TAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTA

6. Sequence of pC322mSaCas9-tRNA-sgRNA-tRNA-(CMV-T7-SaCas9-tRNA-spacer-sgRNA scaffold-tRNA-PolyA)

GACGGATCGGGAGATCTCCCGATCCCCTATGGTCGACTCTCAGTACAATCTGCTCTGATGCCG-
CATAGTTAAGCCAGTATCTGCTCCCTGCTTGTGTGTTGGAGGTCGCTGAGTAGTGCGCGAG-
CAAAATTTAAGCTACAACAAGGCAAGGCTTGACCGACAATTGCATGAAGAATCTGCTTAGGGT-
TAGGCGTTTTGCGCTGCTTCGCGATGTACGGGCCAGATATACGCGTTGACATTGATTATTGAC-
TAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGT-
TACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGAC-
GTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGAC-
GTCAATGGGTGGACTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCAT-
ATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAG-
TACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTAC-
CATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGAT-
TTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGG-
GACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTAC-
GGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCTAACTAGAGAACCCAC-
TGCTTACTGGCTTATCGAAATTAATACGACTCACTATAGGGAGACCCAA-
GCTGGCTAGCCTCGAGATGGCCCCCAAGAAGAAGAGGAAAGTGGGCATCCACGGAG-

Accepted

TGCCAGCCGCTAAGCGCAACTACATCCTGGGCCTGGACATCGGAATCACCTCCGTGGGATAC-
GGCATCATCGACTACGAGACCCGCGACGTGATCGACGCTGGAGTGAGGCTGTTCAAA-
GAGGCCAACGTGGAGAACAACGAGGGCAGGAGAAGCAAGAGAGGAGCTCGCAGGCTGAAGA-
GACGCAGGAGACACAGAATCCAGCGCGTGAAGAAGCTGCTGTTCGACTACAACCTGCTGAC-
C G A C C A C T C C G A G C T G A G C G G C A T C A A C C C C T A C -
GAGGCCAGGGTGAAGGGACTGTCCCAGAAGCTGAGCGAGGAAGAGTTTTCCGCCGCTCTGCTG-
CACCTGGCTAAGCGCAGGGGCGTGCACAACGTGAACGAGGTGGAAGAGGACACCGGAAAC-
GAGCTGAGCACCAAGGAGCAGATCTCCCGCAACAGCAAGGCCCTGGAGGAGAAGTAC-
G T G G C T G A G C T G C A G C T G G A G A G G C T G A A G A A G G A C G G C G A G G T G C G C G -
GATCCATCAACAGGTTCAAGACCAGCGACTACGTGAAAGAGGCCAAGCAGCTGCTGAAGGTG-
CAGAAGGCTTACCACCAGCTGGACCAGTCCTTTATCGACACCTACATCGACCTGCTGGAGAC-
C A G A C G C A C C T A C T A C G A G G G A C C A G G A G A G G G A A G C C C A T T C G -
GATGGAAGGACATCAAGGAGTGGTACGAGATGCTGATGGGACACTGCACCTACTTTCCTGAG-
GAGCTGAGATCCGTGAAGTACGCCTACAACGCTGACCTGTACAACGCCCTGAACGAC-
CTGAACAACCTGGTGATCACCCGCGACGAGAACGAGAAGCTGGAGTACTACGA-
GAAGTTCCAGATCATCGAGAACGTGTTTAAGCAGAAGAAGAAGCCCACCCTGAA-
GCAGATCGCCAAGGAGATCCTGGTTAACGAAGAGGACATCAAGGGCTACAGGGTGACCAG-
CACCGGAAAGCCTGAGTTCACCAACCTGAAGGTGTACCACGACATCAAGGACATCACCGCTA-
GAAAGGAGATCATCGAGAACGCCGAGCTGCTGGACCAGATCGCTAAGATCCTGACCATCTAC-
CAGAGCTCCGAGGACATCCAGGAAGAGCTGACCAACCTGAACTCCGAGCTGACCCAGGAAGA-
G A T C G A G C A G A T C A G C A A C C T G A A G G G C T A C A C C G G A A C C C A C A A C -
CTGTCCCTGAAGGCCATCAACCTGATCCTGGACGAGCTGTGGCACACCAACGACAAC-
CAGATCGCTATCTTTAACAGACTGAAGCTGGTGCCTAAGAAGGTGGACCTGTCCCAG-
CAGAAGGAGATCCCAACCACCCTGGTGGACGACTTCATCCTGAGCCCCGTGGTGAAGA-
GATCCTTTATCCAGAGCATCAAGGTGATCAACGCCATCATCAAGAAGTACGGCCTGCCAAAC-
GACATCATCATCGAGCTGGCCAGGGAGAAGAACTCCAAGGACGCTCAGAAGATGATCAACGA-
GATGCAGAAGCGCAACAGGCAGACCAACGAGAGAATCGAGGAGATCATCCGCACCACCGG-
C A A G G A G A A C G C C A A G T A C C T G A T C G A G A A G A T C A A G C T G C A C G A C A T G C A G -
G A A G G A A A A T G C C T G T A C A G C C T G G A G G C T A T C C C T C T G G A G G A C -
C T G C T G A A C A A C C C A T T C A A C T A C G A G G T G G A C C A C A T C A T C C C A C -
GCTCCGTGAGCTTCGACAACTCCTTTAACAACAAGGTGCTGGTGAAGCAGGAAGAGAACAG-
CAAGAAGGGAAACAGGACCCCCTTCCAGTACCTGAGCTCCAGCGACTCCAAGATCAGCTACGA-
GACCTTTAAGAAGCACATCCTGAACCTGGCCAAGGGCAAGGGAAGAATCTCCAAGACCAA-
G A A G G A G T A C C T G C T G G A G G A G C G C G A C A T C A A C A G G T T C A G C G T G -
C A G A A G G A C T T T A T C A A C C G C A A C C T G G T G G A C A C C A G A T A C G C -
TACCCGCGGCCTGATGAACCTGCTGAGATCCTACTTCAGAGTGAACAACCTGGAC-
GTGAAGGTGAAGTCCATCAACGGAGGCTTCACCAGCTTTCTGAGGAGAAAGTGGAAGTTTAA-
GAAGGAGAGAAACAAGGGATACAAGCACCACGCCGAGGACGCTCTGATCATCGCCAAC-
GCTGACTTCATCTTTAAGGAGTGGAAGAAGCTGGACAAGGCCAAGAAGGTGATGGAGAAC-
CAGATGTTCGAGGAGAAGCAGGCTGAGAGCATGCCAGAGATCGAGACCGAGCAGGAG-
TACAAGGAGATCTTCATCACCCCCCACCAGATCAAGCACATCAAGGACTTTAAGGAC-
TACAAGTACTCCCACAGGGTGGACAAGAAGCCAAACAGAGAGCTGATCAACGACACCCTG-
TACAGCACCAGGAAGGACGACAAGGGCAACACCCTGATCGTGAACAACCTGAACGGACTGTAC-
GACAAGGACAACGACAAGCTGAAGAAGCTGATCAACAAGTCCCCCGAGAAGCTGCTGATGTAC-
CACCACGACCCTCAGACCTACCAGAAGCTGAAGCTGATCATGGAGCAGTACGGCGACGAGAA-
GAACCCTCTGTACAAGTACTACGAGGAGACCGGAAACTACCTGACCAAGTACAGCAA-
GAAGGACAACGGCCCAGTGATCAAGAAGATCAAGTACTACGGAAACAAGCTGAACGCCCAC-
CTGGACATCACCGACGACTACCCCAACTCCAGGAACAAGGTGGTGAAGCTGAGCCTGAAGCCT-
TACAGATTCGACGTGTACCTGGACAACGGAGTGTACAAGTTTGTGACCGTGAAGAACCTG-
GACGTGATCAAGAAGGAGAACTACTACGAGGTGAACTCCAAGTGCTACGAGGAAGCCAAGAA-
GCTGAAGAAGATCTCCAACCAGGCCGAGTTCATCGCTAGCTTTTACAACAACGACCTGATCAA-
GATCAACGGCGAGCTGTACAGAGTGATCGGAGTGAACAACGACCTGCTGAACCG-
CATCGAGGTGAACATGATCGACATCACCTACAGGGAGTACCTGGAGAACATGAACGATAA-
GAGGCCCCCTAGAATCATCAAGACCATCGCCAGCAAGACCCAGAGCATTAAGAAGTACAG-
C A C A G A C A T T C T G G G C A A C C T G T A T G A A G T G A A A T C T A A G A A -
G C A C C C T C A G A T C A T C A A A A A G G G C A A A A G G C C G G C G G C C A C -

Unedited

GAAAAAGGCCGGCCAGGCAAAAAAGAAAAAGGGATCCTACCCATACGATGTTCCAGATTAC-
GCTTACCCATACGATGTTCCAGATTACGCTTACCCATACGATGTTCCAGATTACGTTTAAAC-
GCGGCCGCTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGCTTAACAA
AGCACCAGTGGTCTAGTGGTAGAATAGTACCCTGCCACGGTACAGACCCGGGTTCGAT-
TCCCGGCTGGTGCAAATTGTGGCGATCAAAGCACCGTTTTAGTACTCTG-
GAAACAGAATCTACTAAAACAAGGCAAAATGCCGTGTTTATCTCGTCAACTTGTTGGCGA-
GATTTTTTAAGCTTAACAAAGCACCAGTGGTCTAGTGGTAGAATAGTACCCTGCCACGG-
TACAGACCCGGGTTCGATTCCCGGCTGGTGCAGGGTCTTCGAGAAGACCTGTTTTAG-
TACTCTGGAAACAGAATCTACTAAAACAAGGCAAAATGCCGTGTTTATCTCGTCAACTTGTT-
GGCGAGATTTTTTCAGAATTCGCGGCCGGCAACTGCGTGCACTTCGTGGCCGAGGAGCAG-
GACTGACACGTGCTACGAGATTTCGATTCCACCGCCGCCTTCTATGAAAGGTTGGGCTTCG-
GAATCGTTTTCCGGGACGCCGGCTGGATGATCCTCCAGCGCGGGGATCTCATGCTGGAG-
TTCTTCGCCCACCCCAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAA-
TAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTT-
GTCCAAACTCATCAATGTATCTTATCATGTCTGTATACCGTCGACCTCTAGCTAGAGCTT-
GGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATT-
GTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAA-
GCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCAC-
TGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAAC-
GCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCAC-
TGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAA-
TACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAG-
CAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCA-
TAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGAC-
GCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTG-
GAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATAC-
CTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCAATGCTCACGCTG-
TAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCAC-
GAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAG-
TCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAG-
CAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACAC-
TAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGG-
TAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAG-
CAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTAC-
GGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGAT-
TATCAAAAAGGATCTTCACCTA-
GATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTT-
GGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTC-
TATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCT-
TACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGAT-
TTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTG-
CAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAG-
TTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCAC-
GCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAG-
TTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTT-
GTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTG-
CATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAAC-
CAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGA-
TAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAAC-
GTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAG-
TTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCAC-
CAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAA-
TAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAA-
GCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAA-
TAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTC

Unedited

7. Restriction endonuclease pattern of plasmid pC322mSaCas9



8. Restriction endonuclease pattern of plasmid pCS2+tRNA



9. Restriction endonuclease pattern of plasmid pCS2+tRNA-mSatyr-sgRNA



10. Restriction endonuclease pattern of plasmid pCS2+tRNA-mSatyr-sgRNA+tRNA

Unedited



11. Restriction endonuclease pattern of plasmid pC322mSaCas9+tRNA-tyr sgRNA+tRNA



Unedited